Filed: 8/1/2025ACC: 0001104659-25-073115
📋 What this filing means
REGENERON PHARMACEUTICALS, INC. filed this quarterly 13F‑HR report disclosing 4 equity positions with a total reported market value of $1.49B. This filing provides a transparent view of the manager's long equity holdings as of the quarter end.
4
Positions
$1.49B
Total AUM (reported)
9.30M
Total Shares
Allocation by class
COMMON STOCK$1.49B100.0%
Portfolio Concentration
Top 3$1.48B100.0%
4–10$389.0K0.0%
Top 3 weight
100.0%
Top 10 weight
100.0%
Voting Authority Distribution
Total shares with voting rights: 9.30M
Sole
Full voting authority
9.30M
shares
% of voting shares100.0%
Shared
Joint voting authority
0.00
shares
% of voting shares0.0%
None
No voting authority
0.00
shares
% of voting shares0.0%
Investment Discretion (by position count)
Sole4
Shared0
Other0
Dominant voting typeSole · 100.0% of voting shares
Institutional Holdings4
Rows:
Alnylam Pharmaceuticals, Inc.
SOLEShares4.44M
TypeSH
Market value$1.45B
97.60%
Sole
4.44M
Shared
0.00
None
0.00
Intellia Therapeutics, Inc.
SOLEShares3.70M
TypeSH
Market value$34.73M
2.34%
Sole
3.70M
Shared
0.00
None
0.00
Adicet Bio, Inc.
SOLEShares968.18K
TypeSH
Market value$590.6K
0.04%
Sole
968.18K
Shared
0.00
None
0.00
Adverum Biotechnologies, Inc.
SOLEShares180.91K
TypeSH
Market value$389.0K
0.03%
Sole
180.91K
Shared
0.00
None
0.00
| Issuer | Class | Shares | Type | Value / Portfolio % | Voting — Sole | Shared | None |
|---|---|---|---|---|---|---|---|
Alnylam Pharmaceuticals, Inc.SOLE | Common Stock | 4.44M | SH | $1.45B 97.60% | 4.44M | 0.00 | 0.00 |
Intellia Therapeutics, Inc.SOLE | Common Stock | 3.70M | SH | $34.73M 2.34% | 3.70M | 0.00 | 0.00 |
Adicet Bio, Inc.SOLE | Common Stock | 968.18K | SH | $590.6K 0.04% | 968.18K | 0.00 | 0.00 |
Adverum Biotechnologies, Inc.SOLE | Common Stock | 180.91K | SH | $389.0K 0.03% | 180.91K | 0.00 | 0.00 |